Company news
Caribou Biosciences, Inc. (NASDAQ:CRBU) news
Caribou Biosciences, Inc. news releases on 6ix. Latest, Jul 13, 2023: Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER…
Press releases — page 2
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
July 12, 2023
Caribou Biosciences Announces Proposed Public Offering of Common Stock
July 12, 2023
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
July 12, 2023
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
July 5, 2023
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 8, 2023
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
May 7, 2023
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
April 16, 2023
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
April 3, 2023
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
March 28, 2023
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
March 28, 2023
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 8, 2023
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
December 11, 2022
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
December 11, 2022
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
November 28, 2022
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
November 20, 2022
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
November 2, 2022
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
October 17, 2022
Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
June 9, 2022
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
May 31, 2022
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
May 15, 2022
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
May 11, 2022
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
May 10, 2022
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
May 8, 2022
Caribou Biosciences to Present at Upcoming Investor Conference
May 2, 2022
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
May 1, 2022
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
April 24, 2022
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 20, 2022
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022
Caribou Biosciences to Present at Upcoming Investor Conferences
March 6, 2022
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 6, 2022
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
January 17, 2022
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results
November 8, 2021
Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer
November 7, 2021
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
September 28, 2021
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
September 26, 2021
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results
September 1, 2021
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
September 1, 2021
Caribou Biosciences to Participate in Citi’s 16Th Annual BioPharma Virtual Conference
August 31, 2021
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
August 24, 2021
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
July 26, 2021
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
July 21, 2021